EyeCRO

Executive Summary

EyeCRO is a preclinical contract research organization (CRO) headquartered in Durham, North Carolina, dedicated exclusively to ophthalmic drug development. Founded in 2010, the company offers a comprehensive suite of services including efficacy, toxicology, and pharmacokinetic studies utilizing a broad array of validated disease models. A key differentiator is its proprietary MiDROPS® drug delivery platform, which enables the formulation of lipophilic small molecules into eyedrops, addressing a significant challenge in ocular therapeutics. By combining specialized CRO capabilities with an innovative delivery technology, EyeCRO positions itself as a valuable partner for biopharmaceutical companies seeking to advance ophthalmic candidates through preclinical stages. The company operates in the private sector and has not disclosed funding details, but its focused expertise and patented platform suggest potential for strategic collaborations and licensing opportunities. EyeCRO's business model benefits from the growing demand for ophthalmic treatments and the trend toward outsourcing preclinical development. Its MiDROPS® platform could attract partners looking to reformulate existing lipophilic drugs or develop new chemical entities with enhanced ocular bioavailability. While the company remains privately held and has not reported major public milestones, its established presence in the CRO space since 2010 indicates operational stability. Future growth will likely hinge on expanding its client base, validating the MiDROPS® platform with partners, and potentially securing external investment or strategic alliances to scale its operations. The company's conviction score reflects a solid niche presence with moderate near-term upside, barring unexpected clinical or regulatory breakthroughs.

Upcoming Catalysts (preview)

• Q3 2026Strategic partnership or licensing deal for MiDROPS® platform with a major pharma company35% success
• Q4 2026FDA acceptance of an IND for a client drug formulated with MiDROPS®20% success
• Q2 2026Series A or early-stage funding round to expand CRO capacity and platform commercialization40% success